PepGen Ltd (PEPG)

Name: PepGen Ltd (PEPG) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: PepGen Ltd (PEPG)

Stock Card

$3.08

$0.01 (0.33%)

As on 28-Aug-2026 16:00EDT

Market cap

$213 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.8

Div. Yield

0 %

PepGen (PEPG) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.98 High: 3.13

52 Week Range

Low: 1.13 High: 7.80

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.8 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-3.1
Debt to Equity

0
Book Value

$1.7
EPS

$-1.5
Face value

--
Shares outstanding

69,259,517

5 Years Aggregate

CFO

$-153.40 Mln

EBITDA

$-181.34 Mln

Net Profit

$-178.24 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
PepGen (PEPG)	-52.7	62.1	102.6	148.4	-17.3	--	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023
PepGen (PEPG)	71.8	-44.0	-49.1
S&P Small-Cap 600	4.0	7.0	13.9
BSE Sensex	9.1	8.1	18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
PepGen (PEPG)	3.1	213.3	0.0	-71.9	--	-53.9	--	1.8
Arrowhead Pharmaceuticals (ARWR)	84.9	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	72.1	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	105.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	351.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	533.8	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	600.7	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	344.8	9,625.4	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	144.3	9,339.4	282.0	82.9	-28.6	11.4	140.1	11.5

Shareholding Pattern

View Details

About PepGen (PEPG)

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO... peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts. Read more

President, CEO, Treasurer, Secretary & Director

Dr. James G. McArthur Ph.D.
President, CEO, Treasurer, Secretary & Director

Dr. James G. McArthur Ph.D.
Headquarters

Boston, MA
Website

https://www.pepgen.com

FAQs for PepGen (PEPG)

What is the current share price of PepGen Ltd (PEPG) Today?

The share price of PepGen Ltd (PEPG) is $3.08 (NASDAQ) as of 28-Aug-2026 16:00 EDT. PepGen Ltd (PEPG) has given a return of -17.32% in the last 3 years.

What is the current PB & PE ratio of PepGen Ltd (PEPG)?

Since, TTM earnings of PepGen Ltd (PEPG) is negative, P/E ratio is not available.
The P/B ratio of PepGen Ltd (PEPG) is 1.78 times as on 28-Aug-2026, a 66 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.